Pieris Pharmaceuticals Reports Financial Results and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pieris Pharmaceuticals Reports Financial Results and Corporate Update for the First Quarter Ended March 31, 2016

BOSTON, MA --(Marketwired - May 11, 2016) - Pieris Pharmaceuticals, Inc . ( NASDAQ : PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer and other diseases, today reported financial results for the first quarter of 2016 and provided an update on the Company's recent developments.

"During the first quarter, we made substantial progress across both our pipeline and partnerships, in our continued efforts to build a world class protein biotherapeutic company with a balanced business model offering diversification of assets and risk mitigation. Our continued progress with our most advanced Anticalin ® program, PRS-080, for anemia of chronic disease, ensures that we are on track to complete the ongoing Phase 1b single ascending dose study in anemia patients by year end. We also advanced according to plan our asthma program, PRS-060, which targets the clinically validated IL-4 receptor (IL-4Ra), as well as our lead immuno-oncology (IO) bispecific program, PRS-343, which targets CD137 and HER-2, with each of these programs remaining on track for first-in-human study initiation in the first half of 2017. We are also advancing our earlier immuno-oncology portfolio, while advancing our partnerships with Roche, Sanofi and Daiichi-Sankyo," said Stephen Yoder, President and CEO. "Looking ahead to the rest of 2016, we expect the advancement of our IO multi-specifics franchise to further validate the repeatability of our Anticalin ® -based approach, with the objective of seeking corporate partnerships in IO beyond our Roche collaboration. Our commitment to novel IO multispecifics remains strong, and our recent PD-1 antibody license agreement with Enumeral Biomedical, which gives Pieris the ability to generate novel multispecifics for cancer involving a fusion of a novel PD-1 antibody with our proprietary Anticalins, ® affords us an opportunity to build an independent and highly competitive position around an established core component of the current IO treatment paradigm."

First Quarter Highlights:

  • Advancing PRS-080 into an ongoing Phase 1 single ascending dose study in anemia of chronic disease, with expected completion by year end
  • Advancing PRS-060 towards IND-enabling studies for moderate to severe asthma, and towards a first-in-human study, expected to commence in 1H17
  • Advancing PRS-343 towards IND-enabling studies and a first-in-patient study for HER-2 positive cancers, expected to commence in 1H17
  • Advancing PRS-342, a potential first-in-class bispecific targeting CD137 and GPC3, through preclinical studies
  • Received a $6.5 million upfront payment from Roche
  • Furthered our corporate collaborations with Roche, Sanofi and Daiichi Sankyo through lead identification, preclinical development and clinical development, respectively

Financial Update:

Cash Position - Cash and cash equivalents totalled $31.2 million at March 31, 2016, compared to $29.3 million at December 31, 2015. The increase was driven primarily by the receipt of the $6.5 million up-front payment from Roche, offset by operating expenses for the quarter.

R&D Expenses   - Research and development expenses were $3.7 million for the quarter ended March 31, 2016, compared to $1.5 million for the quarter ended March 31, 2015. The $2.2 million increase was primarily attributable to a $0.7 million and $0.3 million increase in pre-clinical development costs for our PRS-300 series and PRS-060 programs respectively, and a $1.4 million increase in other research and development activities primarily due to additional personnel-related costs and the 5% license fee due to TUM pertaining to the Roche agreement. These were offset by a decrease in the PRS-080 program of $0.2 million as the Phase 1a trial has been completed.

G&A Expenses - General and administrative expenses for the quarter ended March 31, 2016 were $2.0 million, compared to $2.4 million for the quarter ended March 31, 2015. The $0.4 million decrease in G&A expenses was due to a reduction of professional fees of $0.8 million offset by a $0.3 million increase in personnel-related expenses, including stock-based compensation expense and increased investor relation expenses of $0.1 million.

Net Loss - Net loss was $4.2 million or ($0.10) per share for the quarter ended March 31, 2016, compared to a net loss $3.7 million or ($0.13) per share for the quarter ended March 31, 2015.

Conference Call: Pieris management will host a conference call beginning at 10:00 AM Eastern Time on Thursday, May 12, 2016, to discuss the first quarter financial results and provide a corporate update. You can join the call by dialing +1-877-407-8920 (US & Canada) or +1-412-902-1010 (International) and providing the conference ID: 13603006. An archived replay of the call will be available by dialling +1-877-660-6853 (US & Canada) or +1-201-612-7415 (International).

About Pieris Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin ® , Anticalins ® are registered trademarks of Pieris. For more information visit  www.pieris.com .

Forward Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; projected timing and outcomes of clinical trials; our liquidity and ability to fund our future operations; our ability to achieve certain milestones and receive future milestone or royalty payments; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov , including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and the Company's Quarterly Reports on Form 10-Q.

(tables to follow)

 
 
PIERIS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
 
    March 31,   December 31,
2016   2015
             
Assets:            
  Cash and cash equivalents   $ 31,188,527   $ 29,349,124
  Accounts receivable, net     70,259     -
  Prepaid expenses and other current assets     3,608,102     2,311,385
             
Total current assets     34,866,888     31,660,509
  Property and equipment, net     2,210,389     2,162,771
  Other noncurrent assets     128,020     126,781
             
Total Assets   $ 37,205,297   $ 33,950,061
             
             
Liabilities and stockholders' equity:            
  Accounts payable   $ 1,711,028   $ 1,058,536
  Accrued expenses     2,322,044     1,739,380
  Deferred revenue, current portion     2,464,722     -
             
Total current liabilities     6,497,794     2,797,916
Deferred revenue, net of current portion     3,491,690     -
Other long-term liabilities     39,742     23,852
             
Total Liabilities     10,029,226     2,821,768
             
Total stockholders' equity     27,176,071     31,128,293
             
Total liabilities and stockholders' equity   $ 37,205,297   $ 33,950,061
             
   
   
PIERIS PHARMACEUTICALS, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
   
   
    Three Months Ended March 31,  
    2016     2015  
    (Unaudited)  
Revenues   $ 1,246,644     $ 217,621  
                 
Operating expenses                
  Research and development     3,659,435       1,524,631  
  General and administrative     1,967,883       2,394,323  
Total operating expenses     5,627,318       3,918,954  
                 
Loss from operations     (4,380,674 )     (3,701,333 )
                 
  Interest expense, net     -       (4,170 )
  Other income, net     219,620       769  
Loss before income taxes     (4,161,054 )     (3,704,734 )
  Provision (benefit) for income tax     -       -  
Net loss   $ (4,161,054 )   $ (3,704,734 )
                 
Basic and diluted net loss per share   $ (0.10 )   $ (0.13 )
                 
Basic and diluted weighted average shares outstanding     39,833,023       29,292,855  
                 

Company Contact: Pieris Pharmaceuticals, Inc. Darlene Deptula-Hicks SVP & Chief Financial Officer +1-603-553-5803 deptula@pieris.com Investor Relations Contact: The Trout Group Thomas Hoffmann +1-646-378-2931 thoffmann@troutgroup.com Media Inquiries: Gretchen Schweitzer +49 172 861 8540 gschweitzer@macbiocom.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 81

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 107

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 99

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 86

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 95

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 98

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 39

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 136

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Inventor Launches Handy Solution for Kids' Car Sickness

Updated Category News Views 29

A Fresh Take on an Age-Old Problem Just when you thought the universe had thrown all it could at beleaguered parents, here comes a nifty little accessory tackling those dreaded uphill battles with kids and car rides. Some bright spark from Middleburgh, New York, sick of scrubbing car seats and clothing every other road trip, came up with a clever little invention named...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 85

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading

Top 5 Most Recently Viewed Articles

Cascade Milling Enhances Operations with New Facility Expansion

Updated Category News Views 988

Expansion Plans at Cascade Milling Cascade Milling is thrilled to announce the expansion of its organic flour milling facility. This extensive enhancement involves adding a new building dedicated to boosting production. With organic products becoming increasingly popular, this expansion will help the company meet the growing demands for quality organic flours, grains, and...

Continue Reading
Dollar Tree's Stock Trends: What Investors Should Know Now

Updated Category News Views 158

Dollar Tree Inc. Stock Shows Promising Growth Dollar Tree Inc. (NASDAQ: DLTR) shares are experiencing upward movement recently, indicating a possible emerging trend. Notably, the stock seems to be gaining momentum. Market Dynamics and Recent Developments After being deemed oversold, Dollar Tree's stock has gained interest, particularly following recent earnings reports...

Continue Reading
Important Update for Workhorse Group Shareholders About Call

Updated Category News Views 141

Engaging Shareholders Ahead of Upcoming Conference Call In a crucial step to engage with shareholders, Workhorse Group Inc. (Nasdaq: WKHS) is gearing up for a conference call designed to address significant updates. This call is an opportunity for shareholders to discuss the company's important financial results and recently announced transactions. Call Details for...

Continue Reading
LeafLink's Strategic Acquisition of Leaf Trade to Boost Growth

Updated Category News Views 222

LeafLink Expands Horizons with Leaf Trade Acquisition LeafLink, a prominent name in the cannabis wholesale industry, has recently made headlines with its acquisition of Leaf Trade. This strategic move is set to create a significant impact on the market by streamlining operations and addressing the growing needs of multi-state operators (MSOs) and enterprise-level cannabis...

Continue Reading
Florida's First Behavioral Health Teaching Hospital Unveiled

Updated Category News Views 189

Welcoming Florida's First Behavioral Health Teaching Hospital The TGH Behavioral Health Hospital represents a significant milestone in mental health treatment. This facility offers specialized and personalized care for various behavioral and mental health conditions. Inauguration Ceremony at TGH Recently, leaders from Tampa General Hospital (TGH), Lifepoint Health, and...

Continue Reading